Cougar Biotechnology and the Development of Zytiga

690 views

Published on

Among his many successes in the biotechnology and life sciences industries, executive and investor Dr. Lindsay Rosenwald counts Cougar Biotechnology, Inc., as a major coup for both business and cancer research.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
690
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Cougar Biotechnology and the Development of Zytiga

  1. 1.  Among his many successes in the biotechnology and life sciences industries, executive and investor Dr. Lindsay Rosenwald counts Cougar Biotechnology, Inc., as a major coup for both business and cancer research.  As the co-founder and earliest financier of Cougar Biotechnology, Dr. Lindsay Rosenwald provided the drug development team with the needed resources to advance its innovative work in abiraterone acetate, a valuable tool in prostate cancer treatment that has shown resistance to other cancers.
  2. 2.  Following the acquisition of licensing rights for abiraterone from the UK pharmaceutical company BTG plc, Cougar continued the development of the drug with an eye toward eventual commercialization.  By the end of its phase 2 trials on abiraterone, Cougar and all of its drugs currently under development were purchased by Johnson & Johnson for nearly $1 billion in 2009.  Since then, J&J has acquired FDA approval for Cougar’s flagship drug and markets it as Zytiga in the United States.

×